Novartis sickle-cell drug gets US FDA approval

REUTERS: Novartis on Friday won U.S. approval for its experimental sickle cell disease drug, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance.

The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo.Novartis has forecast that the drug's annual sales will top US$1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

BeiGene drug wins US FDA approval for rare form of lymphomaREUTERS: The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Roche buys US drugmaker Promedior for up to US$1.4 billion to get lung drugSwiss drugmaker Roche is paying up to US$1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »